Keros Therapeutics vs vTv Therapeutics
KROS and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and VTVT compare
Keros Therapeutics is the larger company, worth 2.8 times as much as vTv Therapeutics ($199M against $69.9M).
vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −93.7% for Keros Therapeutics).
vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −572% at Keros Therapeutics.
vTv Therapeutics scores higher on the StockData Score (11 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $199M | $69.9M |
| Share price | $10.03 | $17.69 |
| Change, 1 year | −42.0% | −43.4% |
| Change, 5 years | −82.1% | −67.0% |
| Beta (5Y) | 2.22 | 0.06 |
| Employees | 78 | 26 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.7× | 1.9× (better) |
| P/B | 0.8× (better) | 0.9× |
| FCF yield | −24.4% | – |
| Fair value | – | $45.66 |
| Margin of safety | – | 61.3% |
| Growth | ||
| Revenue growth (TTM) | −93.7% | 216600% (better) |
| Net income growth (TTM) | −543% | – |
| EPS growth (TTM) | −1287% | – |
| Profitability | ||
| Operating margin | −698% | −25.1% (better) |
| Net margin | −572% | −12.9% (better) |
| FCF margin | −334% | – |
| Return on equity | −17.2% | −11.7% (better) |
| Return on invested capital | −755% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 21.96 (better) | 12.48 |
| Altman Z-score | 2.07 (better) | 0.81 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 40.6% |
| Held by insiders | 53.3% | 26.3% |
| Insider net buying, 12 months | −$447K | – |
| Short interest, % of float | 11.7% | 5.0% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.